Ladies and gentlemen, thank you for standing by and welcome to the Elanco Animal Health, Inc, Q2 2021 earnings call. At this time, all participants are in a listen only mode. After the speaker presentation, there will be a question- and- answer session. To ask a question during the session, you will need to press star one on your telephone. If you require any further assistance, please press star zero. I would now invite to hand the conference over to your speaker today, Tiffany Kanaga. Thank you. You may begin. Good morning. Thank you for joining us for Elanco Animal Health second quarter 2021 earnings call. I'm Tiffany Kanaga, Head of Investor Relations. Joining me on today's call are Jeff Simmons, our President and Chief Executive Officer, Todd Young, our Chief Financial Officer, and Katy Grissom from Investor Relations. As always, during this conference call, we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to a number of factors, including those listed on slide two and those outlined in our latest Forms 10-K and 10-Q filed with the Securities and Exchange Commission. The information we provide about our products and pipeline is for the benefit of the investment community. It is not intended to be promotional and is not sufficient for prescribing decisions. You can find our press release and the slides referenced on this call in the investor section of elanco.com. The slides and the press release also contains further information about the non-GAAP financial measures that we will discuss today during this call. After our prepared remarks, we'll be happy to take your questions. I will now turn the call over to Jeff to provide the highlights. Thanks, Tiffany. Good morning, everyone. As I reflect on our progress in the nearly eight months since our investor day, we see evidence that our transformation is creating sustainable, long-term value for our customers, our shareholders, and our global Elanco team. Our results demonstrate we are executing against the strategy we laid out in December. Second quarter revenue, EBITDA, and EPS on slide four were all above our expectations, continuing to build on the strong momentum our business has shown since closing the Bayer acquisition a year ago. Revenue of $1.279 billion surpassed the midpoint of our guidance range by nearly $40 million, with out-performance in both sides of our now relatively balanced business between pet health and farm animal. Our adjusted EPS of $0.28 was $0.04 above the midpoint of guidance, including an approximately $0.03 headwind from discrete items in the quarter that pushed our tax rate to nearly 30%, more than offset by approximately $0.07 of operating improvement. Adjusted EBITDA of $291 million was $29 million above the midpoint, demonstrating good flow-through and showing significant headway toward our long-term margin targets. Today, we are raising our 2021 full year revenue guidance for the third time by $15 million at the midpoint to $4.68 billion-$4.73 billion. The business is delivering beyond our long-term growth algorithm, providing total revenue up 5%-7%. This includes approximately 4%-5% for our underlying business, with a reduced innovation range entirely due to external challenges for ZoaShield, which I'll discuss later, that is more than offset by portfolio gains in a good industry backdrop. While we exit the second quarter with strong momentum, we're taking a balanced approach to the rest of the year, factoring in many moving pieces, including seasonality, moderation, and pandemic-driven pet health tailwinds in the vet clinic, and ongoing competitive dynamics. During the second quarter, we made two strategic moves with some near-term implications and important medium and long-term benefits. First, we announced the bolt-on acquisition of KindredBio, which contributes three potential blockbusters alongside our own dermatology assets and more quickly build a presence in this essential part of the industry. The transaction also provides attractive shots on goal in other therapeutic fields, including securing full ownership of the canine parvovirus therapy. We've completed antitrust review and expect the transaction to close this month. Second, we announced the exit of the three manufacturing sites. In further streamlining our footprint, we're accelerating our gross margin efforts, reducing annual CapEx and improving working capital. Todd will provide details on how these two decisions impact our revenue, EBITDA, and EPS in 2021. Both strategic moves are examples of Elanco's increasing position of strength from continued transformation, driving value creation. We're taking the next steps in our journey to build a global independent fit-for-purpose animal health leader with consistent double-digit adjusted EBITDA and adjusted EPS growth in a durable industry. Moving now to overall pet health for the quarter on slide five. The global business drove approximately 2/3 of the upside versus the midpoint of the guidance, reaching $685 million in revenue for the quarter, with continued good execution in a competitive but favorable pet industry. As you know, pet spending has many structural tailwinds, which were amplified during the pandemic. Industry research shows that the number of U.S. pet-owning households surged by nearly 6% in 2020 versus the slightly positive pre-COVID run rate. This trend is not isolated to America, with 3.2 million U.K. households having acquired a pet since the start of the pandemic, and a 2020 survey by the Japan Pet Food Association showing a 15% increase in dog and cat ownership. This increased pet ownership also drove greater vet clinic traffic in the second quarter. Trends were most robust in April, up strong double digits against last year's quarantine impacts. Our Pet Health vaccine business was a standout in the quarter in this beneficial vet clinic backdrop. Vaccines were a key driver of Elanco's 2% improvement in price, reinforcing that our channel strategy is working and creating real demand. Our aggregate channel inventory levels at distribution remain consistent with prior quarters in the U.S. and across the global business. Turning to parasiticides, second quarter global Seresto revenue was $129 million, down 1% year-over-year, and global A-family revenue was $148 million, down 3%. Both faced similar dynamics with a tough comparison against last year's retailer-driven stock-in. Seresto also lapped a meaningful increase in points of distribution at certain major retailers. Additionally, cooler and wetter weather in May across many parts of the U.S. impacted seasonal traffic in the broader OTC channel, as seen in the Nielsen data. Seresto and A-family trends rebounded in June alongside the industry with more favorable weather. Both achieved gains outside the U.S. in the quarter, leading our overall performance in international Pet Health. We remain on track toward full-year expectations for Seresto. The brand's resilient performance demonstrates high levels of confidence among consumers and veterinarians. Let me add that the EPA's 60-day public comment period, which opened July 13th following an NGO petition, is a standard and expected practice. We have full confidence in Seresto's strong safety profile, which is supported by registrations from more than 80 regulatory bodies around the world and our robust pharmacovigilance process. We continue to see a long runway to grow this trusted brand. Rounding out parasiticides, the Credelio franchise drove healthy growth across its combined platform of U.S. vet clinics, retail, and international, along with the launches of both Credelio Plus and Credelio CAT. In the U.S. market, Credelio maintained robust double-digit EDI growth in the second quarter, representing outbound sales into the vet clinics or alternative channels, and trends remained especially strong at retail. This focused brand is performing well in light of industry innovation, which is driving greater-than-anticipated share erosion from our older defend brand, Trifexis. We will continue to maximize profitability with targeted investments across our portfolio and grow revenue through new innovation as we compete for greater share of the expanding, growing global parasiticide market. Our combined international portfolio is highly competitive in both parasiticides and therapeutics, bolstered by our outperformance from new innovation like Credelio Plus. Finally, in therapeutics, GALLIPRANT continued its global expansion and also posted double-digit EDI growth in the second quarter, with year-to-date share gains in the branded U.S. NSAID market, according to the Kynetec data. While we exceeded second quarter guidance and exit the quarter with good momentum, we head into the remainder of the year with a number of variables to consider. We believe Pet Health is recalibrating back towards normalcy against tougher comparisons and with a natural moderation of tailwinds from the puppy boom. We're watching vet clinic trends in light of the limited practice capacity and labor constraints. We're monitoring pet ownership trends as the economy opens up, offset by potential impacts from the Delta and other variants. Additionally, we recognize the increasing competitive nature of the industry, especially in the U.S. endectoparasiticides. In balance, our Pet Health strategy is tracking to overall expectations. Innovation is performing ahead of plan, driving growth alongside focused brand contributions. We have established omni-channel leadership and digital initiatives to generate long-term growth, with expansion in new regions like China, all supporting our full-year outlook and more consistent and competitive levels of Pet Health growth over time. Turning now to our Farm Animal business. In the second quarter, we saw demand-driven improvement in our U.S. cattle and swine businesses, with protein benefiting from a return to food service. The first half of 2021 also benefited from higher numbers of cattle on feed. Elevated and volatile feed costs continue to pressure producer economics, likely extending through the back half of the year. However, they enhance the value proposition for our efficiency products like Skycis, Optaflexx, and Rumensin, which all outperformed our forecasts in the quarter. In China swine, we experienced impacts from the reemergence of African swine fever. Hog prices ended the quarter down about 65% since the start of the year, severely pressuring profitability for Chinese producers. The sow herd reduction is likely to also impact the third quarter. Overall, we still expect our China business to deliver at least a percentage point of growth to total Elanco revenue in 2021. Finally, international poultry and aqua remain negatively affected by unfavorable macroeconomic conditions and reduced consumption as expected, but are exhibiting green shoots of industry improvement. We are seeing easing pressure on CLYNAV as salmon prices improve, averaging up double digits year-over-year during the quarter. CLYNAV is also beginning to benefit from our recently published phase IV study, demonstrating superior ROI versus alternatives. Q2 also saw a very robust lift from the timing of aqua orders shifting into the period from the third quarter. While we do remain cautious around these businesses, we anticipate overall improvement ahead against a soft COVID-driven comparison. As you will see on slide six, our second quarter outperformance is driven by disciplined execution against our strengthened and expanded IPP strategy. I'd like to share more on our innovation progress on slide seven with details around the eight launches planned this year. Pet health innovation is running above expectations, and I'm pleased with the global team's commercial execution around each of these three launches. Credelio Plus is exceeding plan in Japan and Europe and is on track to launch in Australia in Q3 in time for the local parasiticide season. Differing thresholds around heartworm prevention prevent us from bringing this product to the U.S., Credelio Plus is proving to be very competitive in the $1.5 billion international market. Meanwhile, Credelio CAT and Elura are growing our feline portfolio. In farm animal, Increxxa is faring well in a competitive and unprecedented market dynamic. It remains early days for Experior, but we're making important strides towards achieving packer ecosystem integration with continued potential for blockbuster status. Experior's value proposition is being validated in the field, and packer acceptance is growing, now reaching seven packers versus one at the end of Q1. The first Experior customers have now reordered product and expanded use. Finally, ZoaShield, which we sourced externally to build our portfolio in the raised-without-antibiotic space. ZoaShield is currently facing greater than anticipated market supply of the leading competitive product. As a result, we're taking a prudent approach to total pipeline forecasts in 2021, reducing our innovation revenue outlook by $15 million- $65 million-$85 million. However, we remain confident in the value contributions of ZoaShield to our poultry portfolio. It's important to understand that this year's reduction does not impact 2025 total innovation potential of $600 million-$700 million, which we raised in mid-June with the announcement of the KindredBio acquisition. Before I turn the call over, let me say a few words on the regulatory item. On July 1, Elanco received a subpoena from the SEC relating to our channel inventory and sales practices prior to mid-2020. We've cooperated in providing documents and information to the SEC, and we'll continue to do so. We believe strongly that our actions were appropriate. I'd like to just stop and thank our entire global team for continued diligent execution and focus during these unprecedented times. From our South Africa colleagues determining how to reach customers amid riots, to those in Vietnam sleeping in our plant to ensure supply amid another COVID lockdown. Their commitment to our purpose is unwavering and inspiring. I'll hand it over to Todd to provide more color on our results and our outlook. Thanks, Jeff. Slide eight summarizes our financial performance highlights, including our reported net income and earnings per share. On slides 31-40 in the appendix, you can find a summary of the adjustments made to the reported results to arrive at our adjusted presentation. I'll focus my comments on our second quarter adjusted measures in order to provide insights on the underlying trends in our business. Please refer to today's earnings press release for a detailed description of the year-over-year changes in our reported results. Looking at the adjusted measures on slide nine, you'll see that total Elanco revenue increased 118% in the quarter on a reported basis, with 5 points of benefit from foreign exchange for legacy Elanco. Our second quarter revenue on a pro forma combined company basis would've represented growth of approximately 10%, assuming the Bayer acquisition had happened at the start of the year and adjusting for the impact of strategic distribution changes. On slide 10, there's a visual representation of our revenue outperformance versus the guidance range we provided in May. The key drivers, in order of magnitude, were commercial execution in our international pet health business, continued improvement in U.S. cattle and swine, currency tailwinds, and order phasing in aqua. Adjusted gross margin as a percent of revenue was 57%, an increase of 750 basis points compared to the second quarter of last year. The year-over-year improvement reflects the Bayer acquisition that dramatically increased our exposure to the rapidly growing pet health side of animal health. Remember also that this higher-margin portfolio is first-half weighted due to the northern hemisphere's flea and tick season. Additionally, we saw the benefit of positive price and volume on Elanco's legacy portfolio and continued productivity gains. The sequential deceleration of 220 basis points versus the first quarter includes impact from a temporary plant shutdown due to a weather-induced power outage, logistics costs, and the shift of some expenses into the second quarter with the legacy Elanco ERP cutover, as discussed last quarter. Total operating expense increased 116% in the second quarter, driven by the addition of the Bayer Animal Health business. At $475 million, the amount was $42 million above the first quarter and includes the previously identified approximately $30 million shift of investments into the second quarter. The delayed expenses included more opportunistic and effective phasing for direct-to-consumer and digital advertising. Operating income increased 268%, reflecting the Bayer Animal Health acquisition, our top-line execution, expense leverage and discipline, and synergy execution. The sequential step-down of $47 million from the first quarter is attributable to the sequential gross margin and shifting investment impacts I just described. Our adjusted EBITDA was $291 million, and our adjusted EBITDA margin for the quarter was 22.8%. At the bottom line, Q2 adjusted net income increased 274% to $135 million, reflecting our effective tax rate of 29.6%. Two discrete items primarily drove our rate above our prior full-year forecast of 21%-22%. First, tax rate changes in several jurisdictions required the remeasurement of our deferred tax assets and liabilities, with the net impact adding nearly $5 million to our Q2 tax expense. The largest impact was in the U.K., where the tax rate increased from 19%- 25%, resulting in $3 million in additional tax expense. This impact will not repeat. Second, we finalized a number of international tax return to provision and transfer price adjustments that increased our expense by nearly $4 million. For the back half of the year, we anticipate an effective tax rate in the 22%-23% range. Let's discuss our revenue performance more closely. On slide 11, you will see a breakdown of the contribution from legacy Elanco and legacy Bayer portfolios by category. Legacy Bayer products contributed $529 million in the quarter. Pet health drove $685 million of revenue or 54% of total Elanco. Cattle contributed $231 million or 18% of total Elanco revenue in the quarter. Poultry added $179 million, representing 14%. Swine, $113 million or 9%, and aqua, $44 million or 3%. On slide 12, you can see the effect of price, rate, and volume on our revenue performance. The benefit of the Bayer acquisition is reflected in volume. We will continue to report the addition of the Bayer business in volume through the third quarter of 2021 when we lap the transaction close. For the legacy Elanco business, price was up 2% for the quarter, led by pet health vaccines and demonstrating the value of our innovation, the discipline we are applying despite competitive pressures, and enhanced commercial execution, all continued evidence that our channel strategy is working. Farm animal price was flat in the quarter, reflecting competitive dynamics in U.S. cattle and swine. We continue to target a 2% increase for the total business in 2021, with revenue management in focus as we are observing some inflationary pressures in areas such as transportation costs. Slide 13 provides a breakdown of our overall performance between the U.S. and our international operations. We have further outlined our geographic performance by pet health and farm animal, as well as contract manufacturing, all of which benefited from the addition of Bayer. We expect to file our 10-Q shortly, but moving to slide 14, let me offer a few words on working capital, operating cash flow, and debt payoff. In the U.S., consistent with the prior four quarters, we held all distributors at 60-day payment terms. In the second quarter, days sales outstanding stood at 75 days, up from 69 in the first quarter as our average accounts receivable throughout Q2 was higher as a result of Q1 revenue being significantly higher than Q4 revenue. We ended the second quarter with $580 million in cash and equivalents on our balance sheet. We have secured a commitment for additional pre-payable floating rate bank debt of $500 million to refinance our $500 million of senior notes that come due on August 27th. We will use cash from our balance sheet and draw on our revolving credit facility to fund the KindredBio acquisition. Consequently, we expect net leverage of 5.5 times at the end of 2021, in line with our original projection from December 2020. Before I discuss our guidance, I'd like to remind everyone of the 2021 financial impacts from streamlining our manufacturing footprint announced June 9th. We closed the sale of the Shawnee, Kansas site on August 1st, removing $10 million-$20 million of associated contract manufacturing revenue in the last five months of this year. This impact was reflected in the guidance we confirmed when we announced the KindredBio acquisition on June 16th. We do not expect an impact to adjusted EPS from the sale, but we do anticipate a $5 million-$10 million EBITDA headwind in 2021, including an effect on depreciation. Please refer to our press release this morning for the GAAP impact to our second quarter results from this divestment. With respect to the KindredBio acquisition, we expect slight dilution to both reported and adjusted EPS for the full year 2021, an approximately $10 million impact to net loss, and approximately $10 million impact to EBITDA as we continue to execute against KindredBio's R&D programs. Now we'll transition to our full year and third quarter 2021 outlook, starting on slide 16. We are raising our full year 2021 guidance for total revenue and updating EBITDA and EPS for a number of factors, including our second quarter outperformance. We now anticipate 2021 revenue of $4.68 billion-$4.73 billion, including the loss of $10 million-$20 million of contract manufacturing revenue from the Shawnee facility exit. To walk from our last update in June on slide 17, our increased outlook flows through the approximately $40 million outperformance in the second quarter, partly offset by a reduced outlook this year for ZoaShield and the impact of aqua order phasing. Slide 18 offers a refreshed view of the bridge from our 2020 combined company revenue to our 2021 guidance. In comparison to our May update, we now expect innovation to contribute $65 million-$85 million in new revenue. This reduced range is offset by growth in our base portfolio. As a result, we anticipate approximately 4%-5% underlying growth for the year and 5%-7% total growth. Moving to slide 19, we expect adjusted EBITDA of $1.035 billion-$1.075 billion based on adjusted gross margin at 56.75%-57% and OpEx of $1.78 billion-$1.8 billion. Our gross margin rate is being negatively impacted by increased logistics expense and inflationary pressures on our supply chain. The $20 million reduction to the adjusted EBITDA range also reflects the change in our depreciation assumption, including the impact of our manufacturing exits and expenses associated with KindredBio, mostly offset by our Q2 outperformance of nearly $30 million. Our full year spend continues to incorporate strategic investments and commercial growth opportunities. Slide 20 provides the moving pieces informing our updated, adjusted, and reported EPS guidance range. Our adjusted EPS outlook, which is $0.03 lower than the range discussed in May, factors in $0.02 of dilution from KindredBio, $0.02 of impact from the ZoaShield and aqua phasing, $0.03 from logistics and inflation, and $0.03 from the discrete tax items affecting Q2. We are flowing through the $0.07 of operational execution and outperformance from Q2 to arrive at a revised 2021 guidance of $0.97- $1.03. Our outlook demonstrates the underlying fundamentals of our business remain strong into the balance of the year. The reported EPS bridge likewise flows through the second quarter outperformance in the aforementioned items, as well as the $0.46 write-down finalized from the manufacturing streamlining announcement. The impact to reported earnings from integration and standup are sequentially decreasing in magnitude from approximately $80 million in the first quarter of 2021 to approximately $20 million this quarter. Moving to slide 21, we are providing guidance for the third quarter of 2021. We expect revenue of $1.075 billion-$1.1 billion, adjusted EBITDA of $195 million-$220 million, and adjusted EPS of $0.15-$0.19. Our outlook, which is a sequential step down from the first half of the year, reflects the seasonality of our combined company and the resulting quarterly cadence, as detailed in our call in May. Remember, just over 70% of Seresto revenue and just under 60% of the Advantage Family revenue occurs in the first half of the year on average. Given the relative scale of these products and their margin contribution, the revenue timing translates to an outsized first half contribution to EPS as well. Now I'll hand it back to Jeff for closing comments. Thanks, Todd. To summarize, Elanco is moving through 2021 with strong results, extending our track record of execution since acquiring Bayer Animal Health and driving long-term strategic actions with the expected acquisition of KindredBio, further streamlining our manufacturing footprint and delivering on our vision of food and companionship enriching life. We head into the back half of the year with confidence in our ability to drive sustainable double-digit adjusted EBITDA and adjusted EPS growth, anchored by steady growth on the top line. Our fundamentals are healthy with our core R&D pipeline tracking to plan and robust portfolio growth resulting in above algorithm revenue velocity in 2021. Our productivity agenda continues to deliver with rapid action towards synergy capture. Finally, I'd like to express a heartfelt thank you to Katy Grissom as she transitions to a new role in Global Marketing Finance. Katy has been an instrumental part of the IR team during our journey since the IPO, and I look forward to the impact of her contributions in our commercial organization. With that, I'll turn it over to Tiffany to moderate the Q&A. Thanks, Jeff. We'd like to take questions from as many callers as possible. We ask that you limit yourself to one question and one follow-up. April, please provide the instructions for the Q&A session. We'll take the first caller. Again, if you would like to ask a question, please press star, then the number one on your telephone keypad. Your first question is from Michael Ryskin with Bank of America. Thanks. Hi, thanks for taking the question this morning. I want to start on sort of the guide methodology and the rationale from earlier in the year. I think slide 16 in your deck summarizes it really well. You had raised the guide a number of times earlier this year, most recently in May, and now we're in a situation where you're lowering it on adjusted EBITDA, adjusted EPS, despite the solid second quarter. Obviously, that's a little disappointing. I'm just wondering if, given all the moving pieces in the Bayer deal, the moving pieces in the underlying market, it'd be more prudent to take a more conservative approach, leave more wiggle room for things like the ZoaShield update and some of the logistics costs and the inflationary pressures. Mike, appreciate the question. We've been trying to give the, I guess, most consistent and best information we have at the time when providing guidance. When we did the Kindred deal, as well as the streamlining of our manufacturing, those did have impacts on EPS as well as EBITDA. We provided the bridges in the slides to try to clearly show that. Those are the key items. We've had the over-performance from Q2 that we factored in, plus this tax rate impact in Q2 that spiked the tax rate and cost us about $0.03 of EPS as a result of the law changes in the U.K., as well as some return and provision adjustments. Overall, we've been very pleased with the underlying growth in our business. As noted, the portfolio contribution from our products is growing faster now than we had previously communicated, which we view as a very big positive. The one-off with the ZoaShield on supply, again, that's something that we thought would play out differently at the start of the year. We're still confident in our raised-without-antibiotic portfolio going forward. Overall, we're trying to be as clear on the moving pieces. Again, second half is very much in line or slightly better on our total Elanco portfolio than we expected back in May, offset by some of the inflationary jumps on the logistics side, the teams managing. Okay. We'll take the next caller. Your next question is from Umer Raffat with Evercore ISI. Hi, guys. Thanks so much for taking my question. Jeff, in your prepared remarks, you mentioned an SEC is looking into the inventory practices. Could you expand on that a bit more? What specifically are they alleging? Do you expect this to be a multi-year process before any sort of resolution comes? At least that's what's been the observation with similar investigations SEC's done on other companies in the past. Thank you, Umer, for the question. Let me just reiterate. Yes, on July 1 of this year, our company received a subpoena from the U.S. SEC. It was relating to our channel inventory and sales practices prior to the mid-2020 period. The company has cooperated in providing the documents and information to the SEC at this stage and will continue to do so. As I stated, management, starting with myself, believes strongly that our actions were appropriate. Umer, maybe to put this in proper context that I think is important in what you're asking for, first, to continue to keep with the theme of transparency, to ensure continued transparency, that is very important to us. That is why we chose to voluntarily disclose the subpoena we received from the SEC last month. I think secondly, as I discussed today, the scope of the subpoena is related to our channel inventory and sales practices prior to the middle of last year, after we reduced channel inventory and changed our distribution strategy. You can appreciate this, that I'm not able to provide more details since we don't comment on litigation or regulatory investigations. I can say we're cooperating with the SEC, and we believe our actions were appropriate. We remain confident in our business strategy and also the decision to make a change in our distribution channel strategy. Our teams will continue to be highly focused on executing, Umer, against our outlook in 2021 and driving long-term shareholder value, which I think we demonstrated with consistent business performance at or above expectations over the past year. As much as I appreciate the desire for more details that comes with this transparency, at this current time, we do not intend to provide further comment except when in compliance with security laws. We'll take the next caller. Your next question is from Nathan Rich with Goldman Sachs. Hi, good morning. Thanks for the questions. Just two on the revenue outlook for the back half of the year. The change in the expectations for ZoaShield led to a pretty large reduction in the guidance for new products, that $15 million reduction that you called out, especially with pet health running ahead of your expectations with the new launches there. Could you just maybe talk about your updated assumptions for ZoaShield and maybe how we should think about additional variability in the back half of the year? If I could also just ask on the competition in parasiticides, Jeff, that you called out with some of the changing dynamics you've seen. Are you still expecting that $50 million revenue headwind from competition this year? Thank you. Nathan, let me just anchor back on some important points. First, on ZoaShield. It's an externally sourced product to build out our raised-without-antibiotic portfolio, as Todd highlighted. We believe strongly that this portfolio is well-positioned to be competitive in the medium and long term. This is an alternative coccidiostat, and fits nicely as a portfolio play. Let me speak very directly on what has happened. It's currently facing greater than anticipated market supply of a leading competitive product. Said another way, there's currently more supply from this competitive product than we anticipated as we go into these health program rotations with poultry integrators. This dynamic is discrete, maybe a little bit more short-term in nature. It's leading to a reduced innovation outlook for this product. We remain confident in our overall value contributions we see from ZoaShield and our poultry portfolio, and more so, I want to reiterate no change to our 2025 innovation revenue target. That's $600 million-$700 million range that we updated in June with the KindredBio, and more to come. I would pivot too, to the two critical platforms of new products in that portfolio of eight that matter the most, our Credelio platform, again, Credelio Plus, Credelio CAT, exceeding expectations, and Experior tracking very nicely on that track to be a blockbuster that we've talked about. Relative, Nathan, to the parasiticide competition, it's playing out as expected, and as we've even talked about it. New innovation is impacting some of the older brands across the industry, ours and others. Innovation is driving and expanding the parasiticide market. It is growing nicely as an overall segment. The impact has come to our Trifexis a little bit more. When I step back, Nathan, and I look at the pushes and pulls of our global parasiticide strategy, the proof points are pretty evident that things are tracking, and we're in a very strong position. We see the Credelio franchise here in the U.S. and globally growing, driven by vet clinic traffic and a good industry backdrop as well as growth in EDI sales. Credelio Plus, Credelio CAT, as I mentioned, new products. Retail continuing to do well. When I broaden it out even a little further, we're seeing nice growth in international markets. Advantage is doing well in Asia, as we've mentioned. Again, exceeding expectations, and Seresto's on track to meet our 2021 expectations. Pushes and pulls, pipeline progressing. We're in a good place overall in global parasiticides. We'll move to the next caller, please. Your next question is from Chris Schott with JP Morgan. Great. Thanks so much for the questions. I just had two here. I think you mentioned in the opening remarks that there was some moderation in pet health trends reflected in the second half guidance. I'm just hoping you could elaborate a little bit on, is that something that you're seeing already there or expecting? I'm just trying to get a sense of what's kind of leading to that expectation. The second question was on, I think you mentioned weather impacting the OTC business in May. Can you just help us quantify a little bit of what you saw there? I'm just trying to get a sense of, we think about the 2Q results overall, how much of an impact that is. We're trying to think about more of a normalized result on the quarter. Thanks so much. Chris, I would say overall, I want to highlight a few things in these trends. I think that it's a little early to say what's going to stick post the pandemic. As we highlighted, and I think other companies have highlighted, the trends are significant that numbers of pets have gone up globally. Pet visits have gone up globally, U.S. and international. Our simple headline here is we do believe that the 2020 growth that came from COVID will lessen. The direction of the trends and the market changes will not reverse. They will stick. We've seen a rising of the overall level of the marketplace, which is positive. We know when we look at what's really driving the ultimate growth, vet clinic traffic, we believe, will start to go more to that two-year average versus where we are today as we move through the second half. Moving from double-digit growth in those vet clinic traffic to seeing it move to maybe more low single digit. That is what we're predicting and assuming. We're seeing that from the standpoint of just the ability to sustain this, we think is a challenge. I think retail purchasing as well has had, as you know, a significant growth, especially e-commerce, fastest growing segment. We see that lessening a little bit as well, Joe, as two things happen. One, activity goes back up in the household. Two is innovation in the vet market has also driven, I think, some move to the vet market. I think Elanco's well-positioned with omni-channel portfolio and geo expansion. Relative to your second question, yes, we saw a cooler May. We saw a rebound in June. I don't know if we're going to quantify that at this time. Again, what we believe is that the message we would say is, relative to the tough compares, Advantage and Seresto are tracking to our overall expectations for the year. We'll take the next question. Your next question is from Jon Block with Stifel Financial. Great. Thanks, good morning, guys. Todd, maybe for the first one, for the innovation bucket, it seems like the $15 million ZoaShield, it appears as maybe more of a push than loss. When we think about the ramp of the innovation bucket in the next year, is it fair to say that the year two contribution is greater than the year one, just when we try to isolate the innovation bucket revenue contribution to growth going forward? Jeff, to circle back on Seresto, my figure is I think Seresto is up 35% from Q1 2021 to Q1 2019, some of the color you gave last quarter, it looks like Q2 was up 5%. I know you said it got better in June, but maybe if you can just talk about that disparity, why you have the confidence that it's still on track for your 2021 expectations, and just more broadly speaking, why you think it's more weather related than market share? Thanks, guys. Sure, Jon. Thanks for the question. We're not getting into 2022 guidance. As we've noted previously, the innovation portfolio, we have expected it to be growing faster in the second half from a contribution in 2021 to that what it would do in the first half of 2021. You can assume that that ramp would continue in the course of 2022 as Experior or something would continue to lay the groundwork on getting the packer integration and the like. Once that becomes standard feeding protocol in the feed yards, that becomes just standard course that continues to grow. I think it is a reasonable assumption to assume that back half contribution would have been a better ramp into 2022. Jon, great question on Seresto. Let me just highlight, I think at the highest level, you're exactly right on the trends. I'll reiterate that we're tracking overall with the expectations we have. We did know that the ramp that came from COVID was unusual and higher than normal. Here's the things we're looking at. First of all, probably no more work has been done in a four or five-month period than the last four or five months on Seresto. What we would tell you is, one, we stand behind the safety of the product. Two, proprietary research that we've done shows the belief in the product from pet owners and veterinarians. We've increased the advocacy by the veterinarian as well to this product. It's serving a niche and a need when you look at duration and cost and economics. That's important. We've increased our capabilities on digital. I think most importantly is the global kind of focus, especially in international, with our increased dedicated investments and capabilities like digital and omni-channel. With these, as we look at overall good strong IP protection, stronger capabilities as an independent Elanco maybe versus Bayer. Again, we see this as a product with a long runway of value that can help drive overall growth as a key focus brand for our company. Next caller, please. Your next question is from Steve Scala with Cowen. You mentioned the higher tax rate is due in part to higher corporate tax rates in the U.K. Doesn't the U.K. tax rate increase from 19%-25% as of April 2023? If yes, why is the impact occurring now? The second question is one of just curiosity. If Elanco delivers full-year earnings at the midpoint of the range, then 65% of earnings would be delivered in the first half. In 2018 and 2019, about 50% of earnings were delivered in the first half. Also true of 2020, but that was an unusual year. You noted a handful of temporary factors, but I'm wondering if there's any permanent factors that will drive this trend into the future. Thank you. Sure, Steve. Thanks for the question. The remeasurement of the U.K. is really driven by the deferred tax assets and liabilities that are on the balance sheet that are longer term in nature. We've got to take that entire accumulated balance into effect at one time when the tax law rate change is enacted. That's the reason it's happening now versus later is on those longer-term assets. With respect to the EPS bit, yeah, this is the fundamental change that has happened with the Bayer acquisition. With Seresto, historically it's been about 70% of its sales is in the first half of the year. Advantage Family's close to 60% in the first half of the year. That dovetails into about a $250 million difference in the first half of the year versus the second half of the year from those two products. With that, you get a substantially larger EPS impact, just from the timing of those revenue numbers. We expect that will persist. Clearly, as we get growth in different aspects of our business over time, that can affect the mix. Here in 2021, that was expected. That's why when we've given guidance both for Q1 and Q2, we've called it out. Always a little bit of timing and shifts between quarters. If we look at a first half aspect of $0.65 of EPS, that's about the right percentage as you know, for the dollar at the midpoint for the full year. As we go into 2022, we'd expect a similar seasonality to occur. As I mentioned, we called out some phasing of expenses or aqua sales. Those things are always going to happen in a broad-based global business like we have. The seasonality will certainly continue and in line with how we've been guiding since December of last year. Then I think the normalization, Steve, as you look at a Kindred portfolio coming on, we move to non-parasiticide growth in pet health, as well as in Experior and our farm animal business, cattle and poultry. We see this over time with innovation normalizing. At this point in time, yes, the seasonality, as Todd says, is real but overall beneficial to Elanco. We'll move to the next caller. Your next question is from Balaji Prasad with Barclays. Hi, good morning. Two-part questions from me. Firstly, on ASF, I just want to call out some recent developments, especially the outbreak of ASF in the Dominican Republic, and inquire whether this could pose a risk to swine revival for the industry and you. Maybe some specific commentary around the possibilities around ASF entering the U.S. from this region. Secondly, you called out reemerging ASF pressure with falling hog prices. I'm not sure I got the full connection there. Could you comment on that and the expectations around these trends? Thanks. Yes. Great question, Balaji Prasad. Just at a high level, as we noted in our comments, African swine fever did have an impact, as we've talked about in the first half, just overall to the Chinese pig industry. Slaughter rates were unexpectedly high in Q2, and that pushed pork production up. The sudden supply increase impacted some supply-demand, and we saw, again, a decline of about 65% since the start of the year, as I mentioned. We're going to monitor this going forward. Our overall business continues to be very strong in China, but this surge we saw in the first quarter will lessen as we go into the second half. If I look at African swine fever specifically, even in the Dominican, and the risks of that, I believe all the right measures are being taken in place by the U.S. and Mexican industries. Biosecurity is at a different place than it was in China when the virus hit China. I'm confident that at this point in time, first, it doesn't have any material impact on our business in Latin America, and I do believe that the industry has the right things in place as we go forward. Thanks. Thanks. We'll move to the next question. Your next question is from Elliot Wilbur with Raymond James. Thanks. Good morning. Wanted to ask a question around synergy target progression and cash cost spending against that. I presume your 2021 synergy targets are in fact intact. Specifically wanted to focus more on the cash costs associated with realizing those synergies, I think it was previously $160 million, just in light of some of the inflationary pressures that we're seeing sort of across markets. A follow-up question for Todd. Can you just talk a little bit about operating cash flow in the quarter, just what that number was? I know it's still early days in the integration here. There's lots of moving parts on the working capital side. If there's anything that you could give us at this point to sort of help us think about operating cash flow conversion relative to adjusted net or adjusted EBITDA. Any help there in trying to model operating cash flow going forward? Thanks. Sure, Elliot. Thanks for the question. Synergy tracking is doing very well. The team's delivered on the productivity initiatives. Our manufacturing team continues to over-deliver in this area of finding opportunities to reduce the number of heads needed to drive our manufacturing facilities and continuing to capture that. A large part of the cash cost to capture those synergies related to the layoffs that we did with the restructuring announcements from September of last year, and then in January. From an inflationary pressure, that has less of an impact. We're also doing a lot of combination of purchasing, especially with media spend and other agency-related costs. We are fighting against some inflationary pressure there, but we have better buying power now as a combined company with Bayer. Overall, feel good about how that is tracking. As we look at the cost to both integrate Bayer as well as to set up our separate ERP system, pleased that we went from an $80 million of cash spend in Q1 to only $20 million in Q2, and that's with us going live on the ERP system in Q1, most of the integration from Bayer being completed. That is getting lower. Now, a lot of work to be done, a lot of great work by our global team to use the new system, transition to new processes and the like. We are continuing to stabilize the system. We'll be looking towards, all right, how do we integrate the TCS system that Bayer's business is being run on versus our SAP S/4HANA system where we're operating our business on to integrate those in to drive additional savings in the back half of the 2025 timeframe we've talked about. All those things in play. With respect to operating cash flow, we will be filing the 10-Q shortly. As a reminder, in Q1, we had $22 million of operating cash flow. In Q2, operating cash flow jumped to $149 million. Again, that's the continued execution on these items of the integration popping up and then just continued cash conversion on our working capital goals and the like. Overall, tracking very well on all those items as we move through 2021. We'll take our last question. Your last question is from Navann Ty with Citi. Hi. Good morning. Can you comment on the higher cost? I think you mentioned higher transportation costs. Is that company specific or otherwise? A follow-up on ZoaShield. Are you able to comment on the supply and also the demand dynamics, and what did you expect and what has differed from your expectations? Thank you. Yeah. Navann, thanks for the question. I think, overall, the logistics cost and just the global freight and the mechanisms to get product moved across the world continues to be more disrupted by the COVID and the bounce backs and labor issues than I think we expected. We're seeing some inflation playing in there as well. Teams opening up different trade routes. We're dealing with this in a very proactive manner, we are seeing those costs come through and wanted to highlight it. From a pricing standpoint, we continue to think we will get a 2% price improvement across our portfolio in 2021, we look for opportunities in gross debt or other ways to continue to be sure we're not missing out on opportunities on that end from our own level. With respect to the question on ZoaShield, as we've mentioned, this was a dynamic of supply in the market already as poultry producers in the non-antibiotic space look at how they want to operate. This is something that we are focused on. Overall, $15 million on our $4.68 billion-$4.73 billion revenue is a small percentage. We're looking across and very pleased that our other innovation is tracking ahead of expectations, and we'll continue to do that as we look at the business going forward. That's where we land at the moment, and we'll continue to update over the course of 2021. I'll close by, as we close out the first half, thanking all of you for your interest and the questions today, and look forward to working and engaging with you in the second half. Good, strong fundamentals in the marketplace. The strategy is working. Execution is extremely strong in Elanco. Good momentum is highlighted and exceeding our expectations and raising guidance for the third time. Look forward again in engaging with you as we go forward. Thank you for your time today. Ladies and gentlemen, this concludes today's conference call. Thank you for participating. You may now disconnect.